Immunogenic apoptotic cell death and anticancer immunity

82Citations
Citations of this article
96Readers
Mendeley users who have this article in their library.
Get full text

Abstract

For many years it has been thought that apoptotic cells rapidly cleared by phagocytic cells do not trigger an immune response but rather have anti- inflammatory properties. However, accumulating experimental data indicate that certain anticancer therapies can induce an immunogenic form of apoptosis associated with the emission of damage-associated molecular patterns (DAMPs), which function as adjuvants to activate host antitumor immune responses. In this review, we will first discuss recent advances and the significance of danger signaling pathways involved in the emission of DAMPs, including calreticulin, ATP, and HMGB1. We will also emphasize that switching on a particular signaling pathway depends on the immunogenic cell death stimulus. Further, we address the role of ER stress in danger signaling and the classification of immunogenic cell death inducers in relation to how ER stress is triggered. In the final part, we discuss the role of radiotherapyinduced immunogenic apoptosis and the relationship of its immunogenicity to the fraction dose and concomitant chemotherapy.

Cite

CITATION STYLE

APA

Vandenabeele, P., Vandecasteele, K., Bachert, C., Krysko, O., & Krysko, D. V. (2016). Immunogenic apoptotic cell death and anticancer immunity. In Advances in Experimental Medicine and Biology (Vol. 930, pp. 133–149). Springer New York LLC. https://doi.org/10.1007/978-3-319-39406-0_6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free